Opaleye Management Inc. purchased $124K of GRCE (indirect holdings)
Opaleye Management Inc. purchased 60,490 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $2.05 ($2.04–$2.07, $0.12M total) across 3 trades over 2026-10-01 to 2026-10-05.
How this was made
The 30-second read
Why it matters
The insider buy may be interpreted as a positive signal, but the modest dollar amount limits market reaction.
Market read
A small insider purchase with limited immediate trading relevance.
What to watch
The transaction size is modest relative to the company's market cap, limiting price impact.
Background
SEC Form 4 filing discloses an insider purchase by Opaleye Management, a 10% owner of Grace Therapeutics.
Ticker impact
Opaleye Management Inc. purchased 60,490 shares of Grace Therapeutics, raising its holding to 2,858,657 shares.
modest upward pressure as the market prices in the insider purchase
The filing is a primary source disclosure of a 10% owner increasing its stake; such purchases are typically viewed favorably by investors.
Market effects
Limited impact on the biotech sector; insider activity may be noted by sector analysts.
Minimal effect on broader US market indices.
No significant global market relevance.
Counterpoint
The purchase could be a routine portfolio rebalancing rather than a strong confidence signal.
Key entities
- CompanyGrace Therapeutics, Inc.
Biotech firm whose shares were purchased.
- InvestorOpaleye Management Inc.
10% owner executing the purchase.
